BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26991889)

  • 1. Baseline medical comorbidities in adults randomized in the STRIDE trial for psychostimulant use disorders.
    Dela Cruz AM; Carmody T; Greer TL; Rethorst CD; Warden D; Walker R; Trivedi MH
    Am J Addict; 2016 Apr; 25(3):215-20. PubMed ID: 26991889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study.
    Trivedi MH; Greer TL; Rethorst CD; Carmody T; Grannemann BD; Walker R; Warden D; Shores-Wilson K; Stoutenberg M; Oden N; Silverstein M; Hodgkins C; Love L; Seamans C; Stotts A; Causey T; Szucs-Reed RP; Rinaldi P; Myrick H; Straus M; Liu D; Lindblad R; Church T; Blair SN; Nunes EV
    J Clin Psychiatry; 2017; 78(8):1075-1082. PubMed ID: 28199070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute and long-term cannabis use among stimulant users: Results from CTN-0037 Stimulant Reduction Intervention using Dosed Exercise (STRIDE) Randomized Control Trial.
    Vidot DC; Rethorst CD; Carmody TJ; Stoutenberg M; Walker R; Greer TL; Trivedi MH
    Drug Alcohol Depend; 2019 Jul; 200():139-144. PubMed ID: 31129484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.
    Schubiner H
    CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulant reduction intervention using dosed exercise (STRIDE) - CTN 0037: study protocol for a randomized controlled trial.
    Trivedi MH; Greer TL; Grannemann BD; Church TS; Somoza E; Blair SN; Szapocznik J; Stoutenberg M; Rethorst C; Warden D; Ring KM; Walker R; Morris DW; Kosinski AS; Kyle T; Marcus B; Crowell B; Oden N; Nunes E
    Trials; 2011 Sep; 12():206. PubMed ID: 21929768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of co-occurring substance use on 6 month outcomes for young people seeking mental health treatment.
    Baker KD; Lubman DI; Cosgrave EM; Killackey EJ; Yuen HP; Hides L; Baksheev GN; Buckby JA; Yung AR
    Aust N Z J Psychiatry; 2007 Nov; 41(11):896-902. PubMed ID: 17924242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulant use disorders: characteristics and comorbidity in an Australian population sample.
    Sara G; Burgess P; Harris M; Malhi GS; Whiteford H; Hall W
    Aust N Z J Psychiatry; 2012 Dec; 46(12):1173-81. PubMed ID: 22990432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of cocaine and other substance dependence to well-being of high-risk psychiatric patients.
    Havassy BE; Arns PG
    Psychiatr Serv; 1998 Jul; 49(7):935-40. PubMed ID: 9661229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiorespiratory fitness and body composition of stimulant users: A baseline analysis of the STRIDE cohort.
    Stoutenberg M; Rethorst CD; Vidot DC; Greer TL; Trivedi MH
    J Subst Abuse Treat; 2017 Jul; 78():74-79. PubMed ID: 28554607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD.
    Torgersen T; Gjervan B; Rasmussen K; Vaaler A; Nordahl HM
    Atten Defic Hyperact Disord; 2013 Mar; 5(1):59-67. PubMed ID: 23104523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and sample characteristics of the PRISM-E multisite randomized trial to improve behavioral health care for the elderly.
    Levkoff SE; Chen H; Coakley E; Herr EC; Oslin DW; Katz I; Bartels SJ; Maxwell J; Olsen E; Miles KM; Constantino G; Ware JH
    J Aging Health; 2004 Feb; 16(1):3-27. PubMed ID: 14979308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment.
    Shoptaw S; Peck J; Reback CJ; Rotheram-Fuller E
    J Psychoactive Drugs; 2003 May; 35 Suppl 1():161-8. PubMed ID: 12825759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probability and predictors of treatment-seeking for substance use disorders in the U.S.
    Blanco C; Iza M; Rodríguez-Fernández JM; Baca-García E; Wang S; Olfson M
    Drug Alcohol Depend; 2015 Apr; 149():136-44. PubMed ID: 25725934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychiatric emergencies (part II): psychiatric disorders coexisting with organic diseases.
    Testa A; Giannuzzi R; Sollazzo F; Petrongolo L; Bernardini L; Dain S
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():65-85. PubMed ID: 23436669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of patients with dual diagnosis in secondary psychiatric care.
    Luoto KE; Koivukangas A; Lassila A; Kampman O
    Nord J Psychiatry; 2016 Aug; 70(6):470-6. PubMed ID: 27049473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness.
    Bellack AS; Bennett ME; Gearon JS; Brown CH; Yang Y
    Arch Gen Psychiatry; 2006 Apr; 63(4):426-32. PubMed ID: 16585472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a U.S. national sample.
    Krawczyk N; Feder KA; Saloner B; Crum RM; Kealhofer M; Mojtabai R
    Drug Alcohol Depend; 2017 Jun; 175():157-163. PubMed ID: 28432939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comorbidities and race/ethnicity among adults with stimulant use disorders in residential treatment.
    Sanchez K; Chartier KG; Greer TL; Walker R; Carmody T; Rethorst CD; Ring KM; Dela Cruz AM; Trivedi MH
    J Ethn Subst Abuse; 2015; 14(1):79-95. PubMed ID: 25580933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Income and employment of people living with combined HIV/AIDS, chronic mental illness, and substance abuse disorders.
    Conover CJ; Arno P; Weaver M; Ang A; Ettner SL
    J Ment Health Policy Econ; 2006 Jun; 9(2):71-86. PubMed ID: 17007485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
    Upadhyaya HP
    J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.